Drug Profile


Alternative Names: SST 0001

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences
  • Class Antineoplastics; Heparins
  • Mechanism of Action Angiogenesis inhibitors; Heparinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 01 Nov 2016 Sigma Tau Research completes a phase I trial in Multiple myeloma (Second-line therapy or greater) in Germany, Israel and Italy (SC) (NCT01764880)
  • 01 Nov 2012 Phase-I clinical trials in Multiple myeloma in Israel (SC) (NCT01764880)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top